Market TodayThemes and Stocks SummaryThematic Stock SearchCrypto SummaryFAQAbout
PFE - Pfizer Inc.
-0.40(-0.91%)8:03:14 PM 9/30/2022
Pfizer Inc. is an American multinational pharmaceutical corporation. It is one of the world's largest pharmaceutical companies and ranked 57 on the 2018 Fortune 500 list of the largest United States corporations by total revenue. Headquartered in New York City, Pfizer develops and produces medicines and vaccines for a wide range of medical disciplines, including immunology, oncology, cardiology, endocrinology, and neurology. Its products include the blockbuster drug Lipitor , used to lower LDL blood cholesterol; Lyrica for neuropathic pain and fibromyalgia; Diflucan , an oral antifungal medication; Zithromax , an antibiotic; Viagra for erectile dysfunction; and Celebrex , an anti-inflammatory drug.
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 


Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

No summary
Related Topics

Stock news

    Biohaven Pharma's (BHVN) ALS Study Fail to Meet Both Endpoints

    Biohaven Pharmaceuticals (BHVN) suffers a setback as verdiperstat fails to meet the primary and secondary endpoints in an ALS study.

    Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks

    The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?

    10 Best COVID Stocks To Buy Now

    In this article, we discuss 10 best COVID stocks to buy now. If you want to see more stocks in this selection, check out 5 Best COVID Stocks To Buy Now. In 2020, the COVID-19 pandemic was the primary driver of global uncertainty, making headlines around the world. The virus took a backseat only recently, […]

    UPDATE 1-Around 3.2 mln Americans received updated COVID boosters last week -CDC

    Around 3.2 million people in the United States received updated COVID-19 booster shots over the past week, the Centers for Disease Control and Prevention said on Thursday. The 7.6 million figure represents only 3.5% of the 215.5 million people in the United States aged 12 or older who are eligible to receive the shots because they have completed their primary vaccination series. The shots are being administered at a slower pace than last year, when the United States initially authorized COVID ...

    EMA Accepts Moderna's (MRNA) Filing for Omicron BA.4, BA.5 Booster

    The EMA accepts Moderna's (MRNA) regulatory filing seeking authorization for bivalent COVID-19 booster vaccine, mRNA-1273.222, designed to target the Omicron BA.4 and BA.5 subvariants.

    Pfizer (PFE), BNTX Seek EU Nod for Omicron Booster in Kids

    Pfizer (PFE) and BioNTech seek to expand the EU label of their Omicron BA.4/BA.5-adapting bivalent COVID vaccine for children. It is already authorized for use in adolescents and adults.

    UPDATE 1-Biohaven's ALS drug fails to meet study goals

    Biohaven Pharmaceutical Holding Company Ltd said on Thursday its experimental drug to treat amyotrophic lateral sclerosis (ALS) failed a clinical study, the second therapy by the drugmaker to fail trials in recent months. The migraine drugmaker in May agreed to an $11.6 billion acquisition deal by Pfizer Inc, which plans to spin off its non-migraine drugs into a new publicly traded company. On Thursday, Biohaven said its drug for ALS did not achieve statistically significant improvement in pat...

    Merck Inks Supply Deal With Sinopharm To Commercialize COVID-19 Pills In China

    Merck & Co Inc (NYSE: MRK) signed a cooperation framework agreement in China for its COVID-19 antiviral pills, which were co-developed by Ridgeback Therapeutics. The pharma giant has granted Sinopharm exclusive import and distribution rights to Lagevrio (molnupiravir). The companies will also negotiate the feasibility of a technical transfer under the framework so that the drug Molnupiravir could be produced and provided in the Chinese mainland market, Global Times reported. While Pfizer's pills